CN108226534A - 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 - Google Patents

一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 Download PDF

Info

Publication number
CN108226534A
CN108226534A CN201810030852.3A CN201810030852A CN108226534A CN 108226534 A CN108226534 A CN 108226534A CN 201810030852 A CN201810030852 A CN 201810030852A CN 108226534 A CN108226534 A CN 108226534A
Authority
CN
China
Prior art keywords
leu
glu
lys
myo5a
albumen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810030852.3A
Other languages
English (en)
Other versions
CN108226534B (zh
Inventor
杨程德
石慧
黄文喜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Kangrun Biotech Co Ltd
Original Assignee
Guangzhou Kangrun Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Kangrun Biotech Co Ltd filed Critical Guangzhou Kangrun Biotech Co Ltd
Priority to CN201810030852.3A priority Critical patent/CN108226534B/zh
Publication of CN108226534A publication Critical patent/CN108226534A/zh
Priority to PCT/CN2018/095067 priority patent/WO2019136948A1/zh
Priority to US16/961,263 priority patent/US20210063415A1/en
Priority to EP18899192.1A priority patent/EP3734283B1/en
Application granted granted Critical
Publication of CN108226534B publication Critical patent/CN108226534B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。可用于鉴别原发和继发性抗磷脂综合征。同时提供一种试剂盒，利用MYO5A蛋白做成，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。本发明MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，提供了一种新的判别抗磷脂综合征的标记物，提供了一种新的应用方向，对判别抗磷脂综合征具有重要意义。

Description

一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
技术领域
本发明涉及免疫技术领域，特别是涉及一种MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用及其试剂盒。
背景技术
APS，又称抗磷脂综合征，是由Harris EN于1985年最先描述的一组以反复动、静脉血栓或习惯性流产为主要临床表现，伴持续性抗磷脂抗体(APA)阳性的综合征。其基本病理改变为血管内血栓形成，各级动/静脉血管血栓可引起相应症状，胎盘小血管血栓可引起流产，因此血栓是APS最突出的临床表现，是目前公认获得性血栓的主要原因。
APS的症状，皮肤表现可见网状青斑、皮肤溃疡、血栓性静脉炎、肢端坏死、网状青斑性脑血栓形成(Sneddon综合征)以及白塞病和恶性萎缩性丘疹病样皮疹。神经系统可见偏头痛、舞蹈病、局限性脑缺血、狼疮样硬化症、牙买加脊髓病(Jamaicanmyelophathy)及Guillain-Barré综合征。内脏梗塞和血栓形成可见脑梗死、脑静脉血栓、心肌梗死、肾梗塞，肺梗塞、肝Budd-Chiari综合征、无菌性骨坏死、习惯性流产，视网膜动、静脉血栓及四肢动脉闭塞等。
提供生物标记物用于判断抗磷脂综合征对于APS的判断甚为必要。
发明内容
本发明的目的在于提供一种标记物用于判断抗磷脂综合征及其试剂盒。
本发明的上述目的通过如下技术手段实现。
提供MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。
优选的，MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。
优选的，上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，用于鉴别原发性抗磷脂综合征。
另一优选的，上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，用于鉴别继发性抗磷脂综合征。
另一优选的，上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，用于同时鉴别原发性抗磷脂综合征和继发性抗磷脂综合征。
优选的，上述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，MYO5A蛋白的序列为，
本发明同时提供一种标记物，为上述任意一项所述MYO5A蛋白产生的抗体，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
本发明同时提供一种试剂盒，利用MYO5A蛋白做成，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
进一步的，上述的试剂盒，选择MYO5A蛋白或其部分序列片段作为核心部分，检测方法为ELISA、化学发光法或者POCT法中的任意一种。
进一步的，上述的试剂盒，将MYO5A蛋白作为核心原料，试剂盒检测识别的目标分子为MYO5A蛋白所产生的抗体包括IgG、IgM或者IgA中的至少一种，检测的样本包括血清、血浆或者组织液。
本发明MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，提供了一种新的判别抗磷脂综合征的标记物，提供了一种新的应用方向，对判别抗磷脂综合征具有重要意义。
附图说明
利用附图对本发明作进一步的说明，但附图中的内容不构成对本发明的任何限制。
图1是MYO5A蛋白的抗体在APS组和疾病对照组间的差异状况结果图。
图2是MY05A蛋白的抗体在APS组和健康对照组间的显著差异的结果示意图。
图3是MY05A蛋白的抗体在原发APS和继发APS组中的差异情况示意图。
具体实施方式
结合以下实施例对本发明作进一步描述。
实施例1。
提供MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。其中，MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。
MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，可用于鉴别原发性抗磷脂综合征、继发性抗磷脂综合征或者同时鉴别原发性抗磷脂综合征和继发性抗磷脂综合征。
MYO5A蛋白的序列为，
下面通过实验对上述结果进行验证说明：
MYO5A蛋白的抗体在APS组和疾病对照组间并没有显著差异，如图1所示。MY05A这个蛋白的抗体只表现出APS组和健康对照组间的显著差异，如图2所示。
将APS组分成原发APS和继发APS组，以期找到亚组之间的差异蛋白抗体，结果如图3，实验发现MYO5A蛋白抗体的表达在原发APS和继发APS组间存在显著差异，而且在原发APS组和其它疾病对照组和健康对照组间均存在显著差异。
本发明MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，提供了一种新的判别抗磷脂综合征的标记物，提供了一种新的应用方向，对判别抗磷脂综合征具有重要意义。
实施例2。
本实施例提供一种标记物，为通过实施例1的MYO5A蛋白产生的抗体，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
实施例3。
本实施例提供一种试剂盒，利用MYO5A蛋白做成，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
具体的，该试剂盒，选择MYO5A蛋白或其部分序列片段作为核心部分，检测方法为ELISA、化学发光法或者POCT法中的任意一种。
该试剂盒，将MYO5A蛋白作为核心原料，试剂盒检测识别的目标分子为MYO5A蛋白所产生的抗体包括IgG、IgM或者IgA中的至少一种，检测的样本包括血清、血浆或者组织液。
本发明利用MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，提供了一种新的判别抗磷脂综合征的标记物，提供了一种新的试剂盒，对判别抗磷脂综合征具有重要意义。
最后应当说明的是，以上实施例仅用以说明本发明的技术方案而非对本发明保护范围的限制，尽管参照较佳实施例对本发明作了详细说明，本领域的普通技术人员应当理解，可以对本发明的技术方案进行修改或者等同替换，而不脱离本发明技术方案的实质和范围。
序列表
<110> 广州市康润生物科技有限公司
<120> 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
<130> GZZRH0504-18-1-015
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1855
<212> PRT
<213> 人(Homo sapiens)
<400> 1
Met Ala Ala Ser Glu Leu Tyr Thr Lys Phe Ala Arg Val Trp Ile Pro
1 5 10 15
Asp Pro Glu Glu Val Trp Lys Ser Ala Glu Leu Leu Lys Asp Tyr Lys
20 25 30
Pro Gly Asp Lys Val Leu Leu Leu His Leu Glu Glu Gly Lys Asp Leu
35 40 45
Glu Tyr His Leu Asp Pro Lys Thr Lys Glu Leu Pro His Leu Arg Asn
50 55 60
Pro Asp Ile Leu Val Gly Glu Asn Asp Leu Thr Ala Leu Ser Tyr Leu
65 70 75 80
His Glu Pro Ala Val Leu His Asn Leu Arg Val Arg Phe Ile Asp Ser
85 90 95
Lys Leu Ile Tyr Thr Tyr Cys Gly Ile Val Leu Val Ala Ile Asn Pro
100 105 110
Tyr Glu Gln Leu Pro Ile Tyr Gly Glu Asp Ile Ile Asn Ala Tyr Ser
115 120 125
Gly Gln Asn Met Gly Asp Met Asp Pro His Ile Phe Ala Val Ala Glu
130 135 140
Glu Ala Tyr Lys Gln Met Ala Arg Asp Glu Arg Asn Gln Ser Ile Ile
145 150 155 160
Val Ser Gly Glu Ser Gly Ala Gly Lys Thr Val Ser Ala Lys Tyr Ala
165 170 175
Met Arg Tyr Phe Ala Thr Val Ser Gly Ser Ala Ser Glu Ala Asn Val
180 185 190
Glu Glu Lys Val Leu Ala Ser Asn Pro Ile Met Glu Ser Ile Gly Asn
195 200 205
Ala Lys Thr Thr Arg Asn Asp Asn Ser Ser Arg Phe Gly Lys Tyr Ile
210 215 220
Glu Ile Gly Phe Asp Lys Arg Tyr Arg Ile Ile Gly Ala Asn Met Arg
225 230 235 240
Thr Tyr Leu Leu Glu Lys Ser Arg Val Val Phe Gln Ala Glu Glu Glu
245 250 255
Arg Asn Tyr His Ile Phe Tyr Gln Leu Cys Ala Ser Ala Lys Leu Pro
260 265 270
Glu Phe Lys Met Leu Arg Leu Gly Asn Ala Asp Asn Phe Asn Tyr Thr
275 280 285
Lys Gln Gly Gly Ser Pro Val Ile Glu Gly Val Asp Asp Ala Lys Glu
290 295 300
Met Ala His Thr Arg Gln Ala Cys Thr Leu Leu Gly Ile Ser Glu Ser
305 310 315 320
His Gln Met Gly Ile Phe Arg Ile Leu Ala Gly Ile Leu His Leu Gly
325 330 335
Asn Val Gly Phe Thr Ser Arg Asp Ala Asp Ser Cys Thr Ile Pro Pro
340 345 350
Lys His Glu Pro Leu Cys Ile Phe Cys Glu Leu Met Gly Val Asp Tyr
355 360 365
Glu Glu Met Cys His Trp Leu Cys His Arg Lys Leu Ala Thr Ala Thr
370 375 380
Glu Thr Tyr Ile Lys Pro Ile Ser Lys Leu Gln Ala Thr Asn Ala Arg
385 390 395 400
Asp Ala Leu Ala Lys His Ile Tyr Ala Lys Leu Phe Asn Trp Ile Val
405 410 415
Asp Asn Val Asn Gln Ala Leu His Ser Ala Val Lys Gln His Ser Phe
420 425 430
Ile Gly Val Leu Asp Ile Tyr Gly Phe Glu Thr Phe Glu Ile Asn Ser
435 440 445
Phe Glu Gln Phe Cys Ile Asn Tyr Ala Asn Glu Lys Leu Gln Gln Gln
450 455 460
Phe Asn Met His Val Phe Lys Leu Glu Gln Glu Glu Tyr Met Lys Glu
465 470 475 480
Gln Ile Pro Trp Thr Leu Ile Asp Phe Tyr Asp Asn Gln Pro Cys Ile
485 490 495
Asn Leu Ile Glu Ser Lys Leu Gly Ile Leu Asp Leu Leu Asp Glu Glu
500 505 510
Cys Lys Met Pro Lys Gly Thr Asp Asp Thr Trp Ala Gln Lys Leu Tyr
515 520 525
Asn Thr His Leu Asn Lys Cys Ala Leu Phe Glu Lys Pro Arg Leu Ser
530 535 540
Asn Lys Ala Phe Ile Ile Gln His Phe Ala Asp Lys Val Glu Tyr Gln
545 550 555 560
Cys Glu Gly Phe Leu Glu Lys Asn Lys Asp Thr Val Phe Glu Glu Gln
565 570 575
Ile Lys Val Leu Lys Ser Ser Lys Phe Lys Met Leu Pro Glu Leu Phe
580 585 590
Gln Asp Asp Glu Lys Ala Ile Ser Pro Thr Ser Ala Thr Ser Ser Gly
595 600 605
Arg Thr Pro Leu Thr Arg Thr Pro Ala Lys Pro Thr Lys Gly Arg Pro
610 615 620
Gly Gln Met Ala Lys Glu His Lys Lys Thr Val Gly His Gln Phe Arg
625 630 635 640
Asn Ser Leu His Leu Leu Met Glu Thr Leu Asn Ala Thr Thr Pro His
645 650 655
Tyr Val Arg Cys Ile Lys Pro Asn Asp Phe Lys Phe Pro Phe Thr Phe
660 665 670
Asp Glu Lys Arg Ala Val Gln Gln Leu Arg Ala Cys Gly Val Leu Glu
675 680 685
Thr Ile Arg Ile Ser Ala Ala Gly Phe Pro Ser Arg Trp Thr Tyr Gln
690 695 700
Glu Phe Phe Ser Arg Tyr Arg Val Leu Met Lys Gln Lys Asp Val Leu
705 710 715 720
Ser Asp Arg Lys Gln Thr Cys Lys Asn Val Leu Glu Lys Leu Ile Leu
725 730 735
Asp Lys Asp Lys Tyr Gln Phe Gly Lys Thr Lys Ile Phe Phe Arg Ala
740 745 750
Gly Gln Val Ala Tyr Leu Glu Lys Leu Arg Ala Asp Lys Leu Arg Ala
755 760 765
Ala Cys Ile Arg Ile Gln Lys Thr Ile Arg Gly Trp Leu Leu Arg Lys
770 775 780
Lys Tyr Leu Arg Met Arg Lys Ala Ala Ile Thr Met Gln Arg Tyr Val
785 790 795 800
Arg Gly Tyr Gln Ala Arg Cys Tyr Ala Lys Phe Leu Arg Arg Thr Lys
805 810 815
Ala Ala Thr Ile Ile Gln Lys Tyr Trp Arg Met Tyr Val Val Arg Arg
820 825 830
Arg Tyr Lys Ile Arg Arg Ala Ala Thr Ile Val Leu Gln Ser Tyr Leu
835 840 845
Arg Gly Phe Leu Ala Arg Asn Arg Tyr Arg Lys Ile Leu Arg Glu His
850 855 860
Lys Ala Val Ile Ile Gln Lys Arg Val Arg Gly Trp Leu Ala Arg Thr
865 870 875 880
His Tyr Lys Arg Ser Met His Ala Ile Ile Tyr Leu Gln Cys Cys Phe
885 890 895
Arg Arg Met Met Ala Lys Arg Glu Leu Lys Lys Leu Lys Ile Glu Ala
900 905 910
Arg Ser Val Glu Arg Tyr Lys Lys Leu His Ile Gly Met Glu Asn Lys
915 920 925
Ile Met Gln Leu Gln Arg Lys Val Asp Glu Gln Asn Lys Asp Tyr Lys
930 935 940
Cys Leu Val Glu Lys Leu Thr Asn Leu Glu Gly Ile Tyr Asn Ser Glu
945 950 955 960
Thr Glu Lys Leu Arg Ser Asp Leu Glu Arg Leu Gln Leu Ser Glu Glu
965 970 975
Glu Ala Lys Val Ala Thr Gly Arg Val Leu Ser Leu Gln Glu Glu Ile
980 985 990
Ala Lys Leu Arg Lys Asp Leu Glu Gln Thr Arg Ser Glu Lys Lys Cys
995 1000 1005
Ile Glu Glu His Ala Asp Arg Tyr Lys Gln Glu Thr Glu Gln Leu Val
1010 1015 1020
Ser Asn Leu Lys Glu Glu Asn Thr Leu Leu Lys Gln Glu Lys Glu Ala
1025 1030 1035 1040
Leu Asn His Arg Ile Val Gln Gln Ala Lys Glu Met Thr Glu Thr Met
1045 1050 1055
Glu Lys Lys Leu Val Glu Glu Thr Lys Gln Leu Glu Leu Asp Leu Asn
1060 1065 1070
Asp Glu Arg Leu Arg Tyr Gln Asn Leu Leu Asn Glu Phe Ser Arg Leu
1075 1080 1085
Glu Glu Arg Tyr Asp Asp Leu Lys Glu Glu Met Thr Leu Met Val His
1090 1095 1100
Val Pro Lys Pro Gly His Lys Arg Thr Asp Ser Thr His Ser Ser Asn
1105 1110 1115 1120
Glu Ser Glu Tyr Ile Phe Ser Ser Glu Ile Ala Glu Met Glu Asp Ile
1125 1130 1135
Pro Ser Arg Thr Glu Glu Pro Ser Glu Lys Lys Val Pro Leu Asp Met
1140 1145 1150
Ser Leu Phe Leu Lys Leu Gln Lys Arg Val Thr Glu Leu Glu Gln Glu
1155 1160 1165
Lys Gln Val Met Gln Asp Glu Leu Asp Arg Lys Glu Glu Gln Val Leu
1170 1175 1180
Arg Ser Lys Ala Lys Glu Glu Glu Arg Pro Gln Ile Arg Gly Ala Glu
1185 1190 1195 1200
Leu Glu Tyr Glu Ser Leu Lys Arg Gln Glu Leu Glu Ser Glu Asn Lys
1205 1210 1215
Lys Leu Lys Asn Glu Leu Asn Glu Leu Arg Lys Ala Leu Ser Glu Lys
1220 1225 1230
Ser Ala Pro Glu Val Thr Ala Pro Gly Ala Pro Ala Tyr Arg Val Leu
1235 1240 1245
Met Glu Gln Leu Thr Ser Val Ser Glu Glu Leu Asp Val Arg Lys Glu
1250 1255 1260
Glu Val Leu Ile Leu Arg Ser Gln Leu Val Ser Gln Lys Glu Ala Ile
1265 1270 1275 1280
Gln Pro Lys Asp Asp Lys Asn Thr Met Thr Asp Ser Thr Ile Leu Leu
1285 1290 1295
Glu Asp Val Gln Lys Met Lys Asp Lys Gly Glu Ile Ala Gln Ala Tyr
1300 1305 1310
Ile Gly Leu Lys Glu Thr Asn Arg Ser Ser Ala Leu Asp Tyr His Glu
1315 1320 1325
Leu Asn Glu Asp Gly Glu Leu Trp Leu Val Tyr Glu Gly Leu Lys Gln
1330 1335 1340
Ala Asn Arg Leu Leu Glu Ser Gln Leu Gln Ser Gln Lys Arg Ser His
1345 1350 1355 1360
Glu Asn Glu Ala Glu Ala Leu Arg Gly Glu Ile Gln Ser Leu Lys Glu
1365 1370 1375
Glu Asn Asn Arg Gln Gln Gln Leu Leu Ala Gln Asn Leu Gln Leu Pro
1380 1385 1390
Pro Glu Ala Arg Ile Glu Ala Ser Leu Gln His Glu Ile Thr Arg Leu
1395 1400 1405
Thr Asn Glu Asn Leu Asp Leu Met Glu Gln Leu Glu Lys Gln Asp Lys
1410 1415 1420
Thr Val Arg Lys Leu Lys Lys Gln Leu Lys Val Phe Ala Lys Lys Ile
1425 1430 1435 1440
Gly Glu Leu Glu Val Gly Gln Met Glu Asn Ile Ser Pro Gly Gln Ile
1445 1450 1455
Ile Asp Glu Pro Ile Arg Pro Val Asn Ile Pro Arg Lys Glu Lys Asp
1460 1465 1470
Phe Gln Gly Met Leu Glu Tyr Lys Lys Glu Asp Glu Gln Lys Leu Val
1475 1480 1485
Lys Asn Leu Ile Leu Glu Leu Lys Pro Arg Gly Val Ala Val Asn Leu
1490 1495 1500
Ile Pro Gly Leu Pro Ala Tyr Ile Leu Phe Met Cys Val Arg His Ala
1505 1510 1515 1520
Asp Tyr Leu Asn Asp Asp Gln Lys Val Arg Ser Leu Leu Thr Ser Thr
1525 1530 1535
Ile Asn Ser Ile Lys Lys Val Leu Lys Lys Arg Gly Asp Asp Phe Glu
1540 1545 1550
Thr Val Ser Phe Trp Leu Ser Asn Thr Cys Arg Phe Leu His Cys Leu
1555 1560 1565
Lys Gln Tyr Ser Gly Glu Glu Gly Phe Met Lys His Asn Thr Ser Arg
1570 1575 1580
Gln Asn Glu His Cys Leu Thr Asn Phe Asp Leu Ala Glu Tyr Arg Gln
1585 1590 1595 1600
Val Leu Ser Asp Leu Ala Ile Gln Ile Tyr Gln Gln Leu Val Arg Val
1605 1610 1615
Leu Glu Asn Ile Leu Gln Pro Met Ile Val Ser Gly Met Leu Glu His
1620 1625 1630
Glu Thr Ile Gln Gly Val Ser Gly Val Lys Pro Thr Gly Leu Arg Lys
1635 1640 1645
Arg Thr Ser Ser Ile Ala Asp Glu Gly Thr Tyr Thr Leu Asp Ser Ile
1650 1655 1660
Leu Arg Gln Leu Asn Ser Phe His Ser Val Met Cys Gln His Gly Met
1665 1670 1675 1680
Asp Pro Glu Leu Ile Lys Gln Val Val Lys Gln Met Phe Tyr Ile Ile
1685 1690 1695
Gly Ala Ile Thr Leu Asn Asn Leu Leu Leu Arg Lys Asp Met Cys Ser
1700 1705 1710
Trp Ser Lys Gly Met Gln Ile Arg Tyr Asn Val Ser Gln Leu Glu Glu
1715 1720 1725
Trp Leu Arg Asp Lys Asn Leu Met Asn Ser Gly Ala Lys Glu Thr Leu
1730 1735 1740
Glu Pro Leu Ile Gln Ala Ala Gln Leu Leu Gln Val Lys Lys Lys Thr
1745 1750 1755 1760
Asp Asp Asp Ala Glu Ala Ile Cys Ser Met Cys Asn Ala Leu Thr Thr
1765 1770 1775
Ala Gln Ile Val Lys Val Leu Asn Leu Tyr Thr Pro Val Asn Glu Phe
1780 1785 1790
Glu Glu Arg Val Ser Val Ser Phe Ile Arg Thr Ile Gln Met Arg Leu
1795 1800 1805
Arg Asp Arg Lys Asp Ser Pro Gln Leu Leu Met Asp Ala Lys His Ile
1810 1815 1820
Phe Pro Val Thr Phe Pro Phe Asn Pro Ser Ser Leu Ala Leu Glu Thr
1825 1830 1835 1840
Ile Gln Ile Pro Ala Ser Leu Gly Leu Gly Phe Ile Ser Arg Val
1845 1850 1855

Claims (10)

1.MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用。
2.根据权利要求1所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，其特征在于：MYO5A蛋白的抗体包括IgG、IgM或者IgA中的至少一种。
3.根据权利要求2所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，其特征在于：用于鉴别原发性抗磷脂综合征。
4.根据权利要求2所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，其特征在于：用于鉴别继发性抗磷脂综合征。
5.根据权利要求2所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，其特征在于：用于同时鉴别原发性抗磷脂综合征和继发性抗磷脂综合征。
6.根据权利要求1至5任意一项所述的MYO5A蛋白的抗体作为生物标记物在判断抗磷脂综合征方面的应用，其特征在于：
MYO5A蛋白的序列为，
7.一种标记物，其特征在于：为如权利要求1至6任意一项所述MYO5A蛋白产生的抗体，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
8.一种试剂盒，其特征在于：利用MYO5A蛋白做成，通过检测是否存在MYO5A蛋白的抗体从而判断是否存在抗磷脂综合征。
9.根据权利要求8所述的试剂盒，其特征在于：选择MYO5A蛋白或其部分序列片段作为核心部分，检测方法为ELISA、化学发光法或者POCT法中的任意一种。
10.根据权利要求8所述的试剂盒，其特征在于：将MYO5A蛋白作为核心原料，试剂盒检测识别的目标分子为MYO5A蛋白所产生的抗体包括IgG、IgM或者IgA中的至少一种，检测的样本包括血清、血浆或者组织液。
CN201810030852.3A 2018-01-12 2018-01-12 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒 Active CN108226534B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201810030852.3A CN108226534B (zh) 2018-01-12 2018-01-12 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
PCT/CN2018/095067 WO2019136948A1 (zh) 2018-01-12 2018-07-10 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
US16/961,263 US20210063415A1 (en) 2018-01-12 2018-07-10 Applications of biomarker in terms of determining antiphospholipid syndrome and reagent kit of biomarker
EP18899192.1A EP3734283B1 (en) 2018-01-12 2018-07-10 Applications of biomarker in terms of determining antiphospholipid syndrome and reagent kit of biomarker

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810030852.3A CN108226534B (zh) 2018-01-12 2018-01-12 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒

Publications (2)

Publication Number Publication Date
CN108226534A true CN108226534A (zh) 2018-06-29
CN108226534B CN108226534B (zh) 2020-06-30

Family

ID=62640925

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810030852.3A Active CN108226534B (zh) 2018-01-12 2018-01-12 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒

Country Status (4)

Country Link
US (1) US20210063415A1 (zh)
EP (1) EP3734283B1 (zh)
CN (1) CN108226534B (zh)
WO (1) WO2019136948A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136948A1 (zh) * 2018-01-12 2019-07-18 广州市康润生物科技有限公司 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
CN113884684A (zh) * 2021-09-10 2022-01-04 上海交通大学医学院 一种活动性结核病多组学整合标志物、试剂盒及检测模型的构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110265193A1 (en) * 2010-04-23 2011-10-27 Cornell University Identification of mutation and method for detecting lavender foal syndrome in the horse
EP2507390B1 (en) * 2009-12-02 2016-03-09 University of Pretoria Oligonucleotides and methods for detecting lavender foal syndrome
WO2017122203A1 (en) * 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU696638B2 (en) * 1993-11-16 1998-09-17 Yamasa Corporation Method of assaying antiphospholipid antibody and kit therefor
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP1692519B1 (en) * 2003-12-03 2010-06-02 Glycominds Ltd. Method for diagnosing diseases based on levels of anti-glycan antibodies
IT1396046B1 (it) * 2009-04-24 2012-11-09 Sorice Complessi fra fosfolipidi e la proteina vimentina e metodo in vitro per la rilevazione di anticorpi contro detti complessi
WO2011022780A1 (en) * 2009-08-27 2011-03-03 South Eastern Sydney And Illawarra Area Health Service Methods for the diagnosis and prognosis of autoimmune disease
EP2726867B1 (en) * 2011-07-01 2016-04-06 Inova Diagnostics, Inc. Method for increasing specificity of diagnostic tests for autoimmune diseases
ES2642723B1 (es) * 2016-05-12 2018-10-22 Servizo Galego De Saúde (Sergas) Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias.
CN206489172U (zh) * 2017-02-16 2017-09-12 天津市柏艾森生物技术有限公司 用于抗磷脂综合征检测的医用采样检测一体化设备
CN108226534B (zh) * 2018-01-12 2020-06-30 广州市康润生物科技有限公司 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2507390B1 (en) * 2009-12-02 2016-03-09 University of Pretoria Oligonucleotides and methods for detecting lavender foal syndrome
US20110265193A1 (en) * 2010-04-23 2011-10-27 Cornell University Identification of mutation and method for detecting lavender foal syndrome in the horse
WO2017122203A1 (en) * 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REIJI YAMAZAKI ET AL.: "Expression of unconventional Myosin Ⅵ in oligodendrocytes.", 《NEUROCHEM RES》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136948A1 (zh) * 2018-01-12 2019-07-18 广州市康润生物科技有限公司 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
CN113884684A (zh) * 2021-09-10 2022-01-04 上海交通大学医学院 一种活动性结核病多组学整合标志物、试剂盒及检测模型的构建方法
CN113884684B (zh) * 2021-09-10 2023-09-15 上海依赛洛森生物医药有限公司 一种活动性结核病多组学整合标志物、试剂盒及检测模型的构建方法

Also Published As

Publication number Publication date
EP3734283A4 (en) 2021-03-03
CN108226534B (zh) 2020-06-30
WO2019136948A1 (zh) 2019-07-18
EP3734283B1 (en) 2023-06-14
US20210063415A1 (en) 2021-03-04
EP3734283A1 (en) 2020-11-04
EP3734283C0 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
Hayman et al. Serum spreading factor (vitronectin) is present at the cell surface and in tissues.
EP0756708B1 (en) Use of human neutrophil lipocalin (hnl) as a diagnostic marker and anti-hnl-antibody preparation
US20080227117A1 (en) Peptides as Biomarkers of Copd
KR101432191B1 (ko) 이식편대숙주 질환의 검출 또는 치료 방법
JP5565607B2 (ja) 敗血症又は多臓器不全の予後診断方法及び予後診断用キット
JP6183809B2 (ja) ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
RU2595854C2 (ru) Способ диагностики злокачественной опухоли
WO2010141469A2 (en) Protein biomarkers and therapeutic targets for autoimmune and alloimmune diseases
WO2008075788A1 (ja) ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬
RU2670052C1 (ru) Антигенный полипептид для выявления в плазме крови иммунного маркера - аутоантитела к vegfr1 и его применение
Yu et al. Inhibition of pathological retinal neovascularization by semaphorin 3A
CN108226534A (zh) 一种生物标记物在判断抗磷脂综合征方面的应用及其试剂盒
JPWO2007114337A1 (ja) 免疫凝集反応試薬キット及び抗原の測定方法
CN108840920A (zh) 一种人CYR61蛋白Ser167位点磷酸化抗原、抗体及其制备方法和应用
RU2739607C2 (ru) Специфически очищенные антитела против пресепсина
Raman et al. Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 “chemosynapse”
US8114607B2 (en) Type IV collagen-like immunoreactive peptide
CN103102392A (zh) 一种维甲酸诱导蛋白16n端多肽及其抗体的制备方法和应用
Haraguchi et al. Serum IgG ACPA-IgM RF immune complexes were detected in rheumatoid arthritis patients positive for IgM ACPA
Han et al. Beta-thromboglobulin radioimmunoassay. A laboratory characterization and evaluation
CN117024586B (zh) 一种抗体组合物及应用于检测血液中ykl-40浓度的方法
Mirshahi et al. Co-purification of arrestin like proteins with alpha-enolase from bovine myocardial tissues and the possible role in heart diseases as an autoantigen
Kawachi et al. Studies on the ‘linear pattern’in renal glomeruli demonstrated with immunofluorescence
KR101828939B1 (ko) 심장형 지방산 결합 단백에 특이적인 단일클론항체와 이를 생산하는 하이브리도마 세포 및 그의 제조방법
JP2016114360A (ja) ヒトｔ細胞白血病ウイルスｈｂｚ蛋白質の検出方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Application of a biomarker in determining antiphospholipid syndrome and its kit

Effective date of registration: 20210621

Granted publication date: 20200630

Pledgee: Bank of China Limited Guangzhou Yuexiu Branch

Pledgor: GUANGZHOU KANGRUN BIOLOGICAL TECHNOLOGY Co.,Ltd.

Registration number: Y2021440000215